The mechanism of action of palmitoylethanolamide, 20 years after Rita Levi-Montalcini started to understand how this special natural molecule happened to inhibit inflammation, has been brought one step forward by the work of the pharmacologists around professor Iuvone.
In an animal model for chronic inflammation they found palmitoylethanolamide (PEA), to inhibit inflammatory pathways via rMCP-5 mRNA expression and Microphtalmia-associated Transcription Factor (MITF) activation.
The administration of PEA in 3 differently dosages, 200, 400 and 800µg/ml, significantly decreased rMCP-5 mRNA and chymase protein expression induced in the chronic inflammation model. These effects were associated with a significant decrease of MITF/DNA binding activity and phosphorylated MITF as well as phosphorylated ERK levels.
De Filippis D, Russo A, De Stefano D, Cipriano M, Esposito D, Grassia G, Carnuccio R, Russo G, Iuvone T. Palmitoylethanolamide inhibits rMCP-5 expression by regulating MITF activation in rat chronic granulomatous inflammation. Eur J Pharmacol. 2014 Jan 16. pii: S0014-2999(13)00949-7. doi: 10.1016/j.ejphar.2013.12.021